Impressive ASX debut for Somnomed
Friday, 27 August, 2004
Sleep device company Somnomed (ASX: SOM) made an impressive debut on the ASX today, opening 30 per cent above the IPO issue price of AUD$0.30 at $0.40.
At the time of writing the company's shares were trading at $0.475, after reaching as high as $0.49.
Somnomed is commercialising a customised mandibular advancement splint device used to prevent snoring and mild to moderate sleep apnoea.
The company raised $12 million in an oversubscribed IPO and will use the funds to expand their production facilities to an initial capacity of 5000 devices annually, in addition to establishing accreditation programs for dentists, who will prescribe and fit the devices to patients.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
